Literature DB >> 7237048

Flutamide in the treatment of metastatic carcinoma of the prostate.

A S Narayana, S A Loening, D A Culp.   

Abstract

Twenty-five patients with metastatic carcinoma of the prostate were treated with Flutamide, a non-steroidal anti-androgen. All patients showed progression; the longest response was 120 weeks. The side effects were nausea, vomiting, breast tenderness and gynaecomastia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237048     DOI: 10.1111/j.1464-410x.1981.tb03157.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

Review 1.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 2.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

3.  A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.

Authors:  Tomoaki Muramatsu; Yasuhito Funahashi; Akiyuki Yamamoto; Naoto Sassa; Yoshihisa Matsukawa; Momokazu Gotoh
Journal:  Nagoya J Med Sci       Date:  2019-11       Impact factor: 1.131

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.